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Introduction
The majority of bladder cancers are urothelial carcinomas (UC) that occur in the urothelial lining and present as either non-muscle invasive (NMIBC) or muscle-invasive bladder cancers (MIBC). Clinically operable MIBC are treated with radical cystectomy or radiotherapy, however up to 50% of the patients relapse [1] . NMIBC tends to recur frequently and it is estimated that 10-20% of NMIBC potentially progress MIBC [2, 3] . A number of genetic and epigenetic alterations have been identified in MIBC, including amplification of ERBB2 and loss of TP53, Retinoblastoma (RB) and the phosphatase and tensin homolog (PTEN) [4] . NMIBC is strongly associated with activating mutations in FGFR3 with a frequency between 60-80% [5] [6] [7] [8] , followed by chromosome 9 deletion (36-66%) and mutations in RAS family genes and in Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha (PIK3CA) [4] . FGFR3 protein is also overexpressed in 42% of bladder tumours without FGFR3 mutations [49] .
FGFR3 is a tyrosine kinase receptor that mediates the effects of Fibroblast Growth Factors (FGFs) [9] . FGFR3 mainly stimulates the RAS-Mitogen-Activated Protein Kinase (MAPK) and Phosphatidylinositide-3 Kinase (PI3K)-AKT pathway and triggers a range of cellular processes such as cell proliferation and differentiation. When activating mutations occur in the germ line, FGFR3 causes several forms of dwarfism: hypochondroplasia, achondroplasia and thanatophoric dysplasia, and malformation of the cerebral cortex [10] [11] [12] [13] . FGFR3 mutations are identified also in several cancer types, including multiple myeloma, cervical, prostate cancer and spermatocytic seminomas [14] . The functional role of FGFR3 mutation in tumour formation was first demonstrated in multiple myeloma [15] , skin hyperplasia in transgenic mice overexpressing mutant FGFR3 [16] and in xenograft models [17] . However the mechanistic role of FGFR3 activation caused by mutations and overexpression in bladder tumourigenesis remains to be elucidated.
We have previously used a mouse line in which K644E, a highly activating mutation in the Fgfr3 kinase domain, is conditionally expressed in the urothelium (UroIICreFgfr3
+/K644E
) to investigate the functional role of Fgfr3 activation in bladder tumourigenesis [18] . These mice did not show any urothelial phenotype, indicating that Fgfr3 activation alone is not sufficient to drive tumourigenesis in the urothelium. However, in combination with K-Ras or β-Catenin, Fgfr3 activation caused tumours in the skin and in the lungs, respectively, suggesting that Fgfr3 is able to induce tumourigenesis in the presence of cooperating mutations [18] . We found that the Pi3k-Akt pathway was highly up-regulated in lung tumours which formed in the presence of Fgfr3 and β-Catenin mutations, while in the urothelium this up-regulation was not observed. This has led us to hypothesise that urothelial tumourigenesis may require increased PI3K-AKT signalling. In humans, activating PIK3CA mutations, including those at the hotspots (E542K, E545K in the helical domain and H1047R in the kinase domain), are found in 13-25% of bladder cancer [31, [41] [42] [43] [44] [45] . Interestingly, FGFR3 and PIK3CA mutations are shown to co-occur [31, [41] [42] [43] [44] [45] . Therefore it was proposed that activation of PI3K-AKT pathway may enhance the effects of FGFR3 mutation [30, 31] .
In this study, we wished to test the synergistic effects of Fgfr3 and Pi3k-Akt signalling activation. PTEN is a well-known inhibitor of PI3K-AKT signalling and previous mouse models demonstrated that the loss of Pten leads to urothelial hyperplasia [19, 20] . Therefore we used the mouse line with Pten deletion as an experimental tool to assess the effects of Pi3k-Akt activation in the presence of Fgfr3 mutation in the urothelium. The urothelium of double mutant mice was thickened and showed abnormal cellular features including enlarged cells and loss of polarity. The mechanisms leading to this phenotype was further investigated for cell differentiation, cell proliferation and apoptosis. Finally, the synergistic effects of mutations in downstream signalling were characterised in the mouse urothelium, and evaluated along the level of FGFR3 overexpression in clinical specimens in the tissue microarray (TMA) platform.
Materials and Methods
Mice: UroIICre transgenic mice [23] were intercrossed with Fgfr3 +/K644Eneo [11] and 
Results
Together with Pten loss, the activating Fgfr3 mutation increases the thickness of the urothelium in mice.
In order to see whether Fgfr3 activation is able to form UC in the absence of Pten, we generated a cohort of UroIICreFgfr3
Pten flox/flox mice. In these mice, the heterozygous Fgfr3 K644E knock-in mutation [11] and deletion of both Pten alleles [24] occurs concomitantly in the urothelium [27] . Cohorts of UroIICreFgfr3
, UroIICrePten flox/flox and UroIICreFgfr3
Pten flox/flox were examined at 5-18 months (Table 1) We observed a severe increase in thickness of the urothelium in , including vacuolisation, condensed cellular appearance, enlargement of cells and nuclei, and loss of polarity (Figure 2A ). High glycogen levels were detected in vacuoles by Periodic acid-Schiff (PAS) staining (n=3) (Figure 2Ag ).
At least one of these cellular features were observed in the majority of (Table 1) .
In order to see whether these abnormal cellular appearances are caused by a change in urothelial cell identities, staining was performed with urothelial markers well-established in mice, UroII (umbrella and some intermediate cells [28] ), Cytokeratin 5 (CK5) (basal cells [29] ) and p63 (basal and intermediate cells [30] ) (Figure 2Ba-c) . In Fgfr3 mutation only (Figure 3d ). This indicates that cell proliferation was increased due to Pten loss. Similar effects were observed in the outermost and intermediate layers, while no significant changes were seen in the innermost basal layer ( Figure S2 ). Very few apoptotic events were observed in all cohorts ( Figure S3 ). Pten flox/flox urothelium.
Changes in downstream signalling associates with abnormal differentiation
We addressed how Fgfr3 and Pten mutations altered their downstream signalling cascades using antibodies for the phosphorylated forms of Erk1/2 (pErk1/2) and Akt(Ser473) (pAkt).
In Controls, pErk1/2 was observed in a patchy fashion in the urothelium, not limited to a particular cell or cell type (n=9) (Figure 4a ). Staining was similar in UroIICreFgfr3
(n=9) and UroIICrePten flox/flox (n=6/9) (Figure 4d, g ). In contrast, in
UroIICreFgfr3 +/K644E
Pten flox/flox samples (n=9/12, 75%) pErk1/2 was seen more in a cellspecific fashion (Figure 4j ), which resembled the overall pattern of UroII and CK5 staining ( Figure 2B ). As this staining was rather unusual, an alternative pErk antibody was also used to confirm this pattern ( Figure S4 ). This observation may suggest the involvement of local MapK signalling dysregulation in pathogenesis of the urothelium through regulation of cell differentiation. However this requires further investigation. The staining of pAkt was absent in Control (n=3), UroIICreFgfr3 +/K644E (n=6) and UroIICrePten flox/flox (n=7) (Figure 4b , e, h), but found to be up-regulated in 55% of UroIICreFgfr3 +/K644E Pten flox/flox samples (n=6/11, Figure 4k ). Cyclin-dependent kinase inhibitor and tumour suppressor p21 was previously shown to be up-regulated in the mouse urothelium in which Pten is deleted [20] . p21 was present most abundantly in the outermost umbrella layer in Control (n=3) (Figure 4c ), and this remained similar in UroIICreFgfr3 +/K644E (n=3) and UroIICrePten flox/flox (n=3) in this study (Figure 4f, i) . However, in UroIICreFgfr3
Pten flox/flox urothelium (n=4), p21 was expressed throughout the urothelium (Figure 4l ). This p21 up-regulation appeared to have coincided with the overall up-regulation of Pi3k-Akt signalling (Figure 4k ), which is in accordance with the evidence in vitro that activation of PI3K-AKT pathway up-regulates p21 [48] . Altogether, these results provide the evidence to support the activation of Pi3k-Akt pathway in the current mouse model, as a result of cooperation between Fgfr3 and Pten mutations together, but not when either mutation was present individually.
Previous studies have investigated mutations in FGFR3 and PI3K-AKT pathway genes [31, [41] [42] [43] [44] [45] [46] [47] and their activation, using antibodies specific to the phosphorylated form of the protein, such as pAKT [43] [44] [45] 47] . Mammalian Target of Rapamycin (mTOR) is downstream of PI3K-AKT signalling, and a candidate for effective therapeutic target [21, 22] . We 
Discussion
FGFR3 mutations are highly associated with NMIBC [5, 32] . A series of studies have shown the frequent co-occurrences of FGFR3 and PIK3CA mutations and evaluated gene alterations in PI3K-AKT pathway in clinical cohorts of bladder cancer [31, [41] [42] [43] [44] [45] [46] [47] . However functional cooperation between Fgfr3 and Pi3k-Akt activation has never been demonstrated before. As both mutations and overexpression of FGFR3 is also highly associated with bladder cancer [49] , our approach was to address the role of Fgfr3 activation using the existing mouse line with Fgfr3 K644E mutation [11, 18] . Although the kinase domain mutations are less common in contrast to S249C in humans [5, 32] , this mouse line offers several advantages as an experimental model, namely because the Cre-Lox construct enables the expression of mutant Fgfr3 in the urothelium-specific fashion and the mutation is highly activating, thus maximising the chance of detectable phenotype. In the absence of available mouse lines with PI3KCA mutations, we turned to a model that enables conditional Pten deletion [19, 20] . Pten is a well-known inhibitor of Pi3k-Akt signalling and it was shown that its deletion resulted in pAkt up-regulation in bladder tumours in mice [21] .
Significantly, while the papillary structures with fibro-vascular cores seen in human NMIBC
were not observed, the urothelium of UroIICreFgfr3 These histopathological features are comparable to hyperplasia and dysplasia, regarded as early stages in the putative model of bladder cancer pathogenesis in humans. To our knowledge, this is a unique observation that has not been reported in any other genetic models of urothelial abnormalities.
Furthermore, up-regulation of pAkt was observed when both Fgfr3 and Pten mutations together, and not in single mutants (Figure 4 ). In humans, higher pAKT level was found in
This article is protected by copyright. All rights reserved 50% bladder tumours independent of stage/grades and is associated with the presence of mutations, including PIK3CA, FGFR3, and both together [43] . Activation of PI3K-AKT downstream protein, mTOR, is confirmed to be strongly associated with pAKT [47] .
Relationship between FGFR3 overexpression and p-mTOR is relatively unstudied and one report showed no statistical association [47] . However, in the current study, although the number of samples analysed was small, we were able to show association of the intermediate level of FGFR3 overexpression with increased p-mTOR (Figure 4m ). In humans, PIK3CA mutations were also found in normal urothelium, indicating that it is an early event [44] .
Altogether, this study provide functional evidence that supports that up-regulation of FGFR3
signalling together with that of PI3K-AKT signalling plays a role in the initiation of urothelial tumourigenesis.
In contrast, the current model with Fgfr3 and Pten mutations did not produce tumours in the life time of the animal models up to 18 months. This indicates that pathogenesis caused by FGFR3 and PI3K-AKT signalling pathway mutations are unlikely to progress unless further mutations occur. Our data in mice show that Fgfr3 and Pten mutations cooperatively promote morphological changes of the urothelium, while not when mutated individually. Previously it was reported that loss of Pten alone leads to urothelial hyperplasia [19, 20] . However, hyperplasia was not observed by Pten loss in the studies by our group [21] and others [22] . In the current study, although mild urothelial thickening was observed in 60% of the UroIICrePten flox/flox mice (Table 1) , this increase was statistically not significant upon quantification (Figure 1i ). An in vitro study using Normal Human Urothelial Cells stably expressing the hotspot PI3KCA mutations showed a large, vacuolated and flattened morphology [33] . Cell proliferation was also increased in cells with helical domain mutant.
Despite the difference that these effects were singly resulted by PIK3CA activation in vitro, the findings are supportive of our observations in mice. This may reflect the complexity of signalling events leading to tumourigenesis in vivo in which multiple gene mutations and epigenetic events are likely to be required.
There are several differences between the natures of our mouse model in relationship to human bladder cancer that may limit the direct interpretation. Firstly, although we used Pten loss as an experimental tool in this study, in humans, occurrence of FGFR3 mutations are associated with NMIBC while PTEN loss with MIBC, and therefore little overlap is expected [4, 41] . FGFR3 mutations and loss of heterozygosity in PTEN are found together only in a small number of cases of TaG1, T1G2, and T2G3 (Table S5 in ([41]). Statistically, PTEN loss was not associated with up-regulation of pAKT in clinical bladder cancer specimens [46] .
Secondly, a study of clinical specimens reported that 85% of tumours with FGFR3 mutations also overexpressed FGFR3 protein [49] . In contrast, changes in Fgfr3 protein level were not apparent in our model ( Figure S1a-d) . This could be due to the expected low level of endogenous protein expressed in the mouse urothelium. The mechanism of FGFR3 mutations leading to an increased protein level is unclear, however the in vitro studies showed that impaired lysosomal degradation of FGFR3 protein was caused by mutations, increasing the stability of FGFR3 mutant protein in the plasma membrane [40] .
FGF signalling inhibitors have been developed and applied in many cancer types [34] .
Inhibition of FGFR had been suggested as a therapeutic option of UC [35] . Several novel drugs against FGFRs, including R3Mab [17] , BGJ398 [36] and AZD4547 [37] , are shown to be effective in cell lines and xenograft models. A recent attempt to re-classify UCs primarily based on molecular features has revealed that FGFR3 mutations and overexpression are associated with a subgroup of MIBC with significantly poor prognosis [38] . Although at a
This article is protected by copyright. All rights reserved low frequency (3-4%), FGFR3 and AKT1 mutations were found to occur together in highgrade UC [43, 46] . Overexpression of FGFR1 is also found in UC across all stages and grades [39] . Further functional studies of FGF and FGFR3 signalling pathway is therefore essential in both NMIBC and MIBC, firstly to allow stratification according to risk of progression and/or recurrence, and secondly to aid in patient selection for potential combination therapies. The mouse cohorts analysed in this study are summarised. Cellular abnormalities observed include vacuolisation, enlarged cells, and loss of cell orientation within the urothelium.
Causes of non-bladder related deaths include infection and lymphoma, and termination due to skin rash on the back owing to Cre-lox recombination occurred in the epidermis [18] .
*UroIICreFgfr3
K644E/K644E mice were sacrificed at the time when kyphosis became prevalent.
This phenotype is due to a low-level of Fgfr3 expression in the presence of homozygous
Fgfr3
K644Eneo allele [11] . This article is protected by copyright. All rights reserved
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